Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP Compared To Sham Patients At 2-Years

Company commits to advancing clinical data for Symplicity with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial

GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).